South Korea
· Delayed Price · Currency is KRW MegaMD Statistics
Total Valuation
MegaMD has a market cap or net worth of KRW 47.46 billion. The enterprise value is 16.48 billion.
| Market Cap | 47.46B |
| Enterprise Value | 16.48B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
MegaMD has 22.07 million shares outstanding. The number of shares has decreased by -0.13% in one year.
| Current Share Class | 22.07M |
| Shares Outstanding | 22.07M |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -2.33% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 4.23% |
| Float | 10.55M |
Valuation Ratios
The trailing PE ratio is 17.92.
| PE Ratio | 17.92 |
| Forward PE | n/a |
| PS Ratio | 1.31 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | 9.79 |
| P/OCF Ratio | 8.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.63, with an EV/FCF ratio of 3.40.
| EV / Earnings | 6.17 |
| EV / Sales | 0.46 |
| EV / EBITDA | 2.63 |
| EV / EBIT | 15.18 |
| EV / FCF | 3.40 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.85 |
| Quick Ratio | 1.77 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.80 |
| Interest Coverage | 6.23 |
Financial Efficiency
Return on equity (ROE) is 4.19% and return on invested capital (ROIC) is 1.32%.
| Return on Equity (ROE) | 4.19% |
| Return on Assets (ROA) | 1.03% |
| Return on Invested Capital (ROIC) | 1.32% |
| Return on Capital Employed (ROCE) | 2.15% |
| Revenue Per Employee | 231.81M |
| Profits Per Employee | 17.12M |
| Employee Count | 156 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 32.73 |
Taxes
In the past 12 months, MegaMD has paid 865.97 million in taxes.
| Income Tax | 865.97M |
| Effective Tax Rate | 24.49% |
Stock Price Statistics
The stock price has decreased by -8.65% in the last 52 weeks. The beta is 0.76, so MegaMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -8.65% |
| 50-Day Moving Average | 2,371.70 |
| 200-Day Moving Average | 2,183.58 |
| Relative Strength Index (RSI) | 43.73 |
| Average Volume (20 Days) | 175,507 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MegaMD had revenue of KRW 36.16 billion and earned 2.67 billion in profits. Earnings per share was 120.00.
| Revenue | 36.16B |
| Gross Profit | 21.37B |
| Operating Income | 1.43B |
| Pretax Income | 3.54B |
| Net Income | 2.67B |
| EBITDA | 6.60B |
| EBIT | 1.43B |
| Earnings Per Share (EPS) | 120.00 |
Balance Sheet
The company has 34.85 billion in cash and 3.87 billion in debt, giving a net cash position of 30.99 billion or 1,403.63 per share.
| Cash & Cash Equivalents | 34.85B |
| Total Debt | 3.87B |
| Net Cash | 30.99B |
| Net Cash Per Share | 1,403.63 |
| Equity (Book Value) | 64.26B |
| Book Value Per Share | 2,910.82 |
| Working Capital | 17.74B |
Cash Flow
In the last 12 months, operating cash flow was 5.74 billion and capital expenditures -885.14 million, giving a free cash flow of 4.85 billion.
| Operating Cash Flow | 5.74B |
| Capital Expenditures | -885.14M |
| Free Cash Flow | 4.85B |
| FCF Per Share | 219.71 |
Margins
Gross margin is 59.10%, with operating and profit margins of 3.95% and 7.38%.
| Gross Margin | 59.10% |
| Operating Margin | 3.95% |
| Pretax Margin | 9.78% |
| Profit Margin | 7.38% |
| EBITDA Margin | 18.24% |
| EBIT Margin | 3.95% |
| FCF Margin | 13.41% |
Dividends & Yields
This stock pays an annual dividend of 60.00, which amounts to a dividend yield of 2.78%.
| Dividend Per Share | 60.00 |
| Dividend Yield | 2.78% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | 2.92% |
| Earnings Yield | 5.63% |
| FCF Yield | 10.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MegaMD has an Altman Z-Score of 2.6 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.6 |
| Piotroski F-Score | 6 |